Serum β-human chorionic gonadotropin (S-β-hCG) is a widely used tumor marker in patients with testicular neoplasia. When elevated in patients with an enlarged testis it is considered as a strong indication of a germ cell tumor. Elevation of S-hCG-like material (S-hCG-1) has been reported in nontesticular non-germ cell tumors including non-Hodgkin’s lymphomas (NHL) as well. It has never been investigated whether testicular NHL is also associated with elevated S-hCG-1. In the present study the relationship of testicular NHL with increased S-hCG-1 was investigated. In the Danish population-based NHL registry, LYFO registry, 12 cases with testicular involvement of the lymphoma at the time of diagnosis and that had S-hCG-1 measured prior to treatment were identified, and cases with elevated S-hCG-1 were analyzed clinicopatho-logically. Of these, 2 patients had elevated levels. Both cases were high-grade, diffuse B-cell NHL in elderly patients. The patients were hemiorchiectomized and after surgery levels of S-hCG-1 declined to normal. The study indicates that S-hCG-1 elevation is quite frequently associated with testicular NHL. The prognostic significance of this elevation remains to be investigated, as does the usefulness of S-hCG-1 as tumor marker for early detection of recurrences and for monitoring the therapy of patients with S-hCG-1-positive NHL.

Keywords:
Chorionic gonadotropin, human, Testicular neoplasia, Lymphoma, non-Hodgkin’s, Lymphoma, diffuse large cell, Lymphoma, extranodal non-Hodgkin’s
This content is only available via PDF.
© 1996 S. Karger AG, Basel
1996
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.